Small Intestinal Submucosa Graft for Repair of Anterior Urethral Strictures
Launched by XIAOYONG ZENG · Dec 21, 2023
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Urethral stricture refers to the abnormal narrowing of the urethral lumen resulting from fibrosis that affects the urethral epithelium and underlying corpus spongiosum. The management of urethral stricture longer than 2 cm a major therapeutic challenge in clinics. Currently available surgical techniques require harvesting of grafts from autologous sites. However, there are numerous disadvantages associated with autografts, such as limited availability and variable quality, donor site morbidity, increased risk of surgical complications; thereby the application of this method is especially li...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients signed informed consent form
- • Patients with a single, longer than 2.0 cm and shorter than or equal to 7.0 cm anterior urethral stricture
- • Patients undergoing substitution urethroplasty for urethral stricture.
- Exclusion Criteria:
- • Patients without surgical indication
- • Subtotal and total urethral strictures
- • Radiation therapy to the abdomen or pelvis
- • Lichen sclerosis related strictures
- • Patients with previous hypospadias repair
- • Neurogenic urinary tract disorders
- • Mental disorders
- • Patients with a known biologic sensitivity or a cultural aversion to the use of porcine materials.
- • Patients with severe dysfunction of heart, lung, liver, kidney and other important organs , endocrine system and blood system.
- • Patient with malignant tumor
- • Patient who cannot be regularly examined due to any circumstances
- • Any clinical state which does not ensure the safe implementation of study procedure (investigator's view)
About Xiaoyong Zeng
Xiaoyong Zeng is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a background in biomedical sciences and extensive experience in clinical trial management, Zeng focuses on developing novel therapeutic approaches and enhancing patient outcomes. His leadership is characterized by a rigorous adherence to regulatory standards and ethical considerations, ensuring that all trials are conducted with the utmost integrity. Through collaboration with leading researchers and institutions, Zeng aims to contribute significantly to the understanding and treatment of various medical conditions, ultimately striving to improve healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported